Citigroup’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $287K | Sell |
81,725
-23,815
| -23% | -$76.2K | ﹤0.01% | 3816 |
|
|
2025
Q4 | $288K | Sell |
105,540
-304,025
| -74% | -$703K | ﹤0.01% | 3833 |
|
|
2025
Q3 | $889K | Sell |
409,565
-305,286
| -43% | -$721K | ﹤0.01% | 3232 |
|
|
2025
Q2 | $1.23M | Buy |
714,851
+176,539
| +33% | +$439K | ﹤0.01% | 3053 |
|
|
2025
Q1 | $1.79M | Buy |
538,312
+54,270
| +11% | +$280K | ﹤0.01% | 2796 |
|
|
2024
Q4 | $3.58M | Buy |
484,042
+275,278
| +132% | +$2.55M | ﹤0.01% | 2294 |
|
|
2024
Q3 | $1.96M | Buy |
208,764
+70,582
| +51% | +$669K | ﹤0.01% | 2685 |
|
|
2024
Q2 | $1.11M | Sell |
138,182
-401,713
| -74% | -$4.3M | ﹤0.01% | 2841 |
|
|
2024
Q1 | $8M | Sell |
539,895
-214,013
| -28% | -$2.49M | 0.01% | 1384 |
|
|
2023
Q4 | $6.13M | Sell |
753,908
-183,511
| -20% | -$960K | ﹤0.01% | 1465 |
|
|
2023
Q3 | $4.27M | Buy |
937,419
+310,118
| +49% | +$2.02M | ﹤0.01% | 1525 |
|
|
2023
Q2 | $4.42M | Sell |
627,301
-635,344
| -50% | -$4.55M | ﹤0.01% | 1570 |
|
|
2023
Q1 | $7.71M | Buy |
1,262,645
+743,295
| +143% | +$5.13M | 0.01% | 1277 |
|
|
2022
Q4 | $3.32M | Sell |
519,350
-50,824
| -9% | -$397K | ﹤0.01% | 1712 |
|
|
2022
Q3 | $5.46M | Buy |
570,174
+90,702
| +19% | +$1.05M | ﹤0.01% | 1502 |
|
|
2022
Q2 | $5.29M | Buy |
479,472
+389,174
| +431% | +$5.1M | ﹤0.01% | 1505 |
|
|
2022
Q1 | $1.5M | Sell |
90,298
-151,661
| -63% | -$2.35M | ﹤0.01% | 2583 |
|
|
2021
Q4 | $4.62M | Buy |
241,959
+119,208
| +97% | +$2.62M | ﹤0.01% | 1896 |
|
|
2021
Q3 | $3.03M | Sell |
122,751
-91,074
| -43% | -$2.15M | ﹤0.01% | 2188 |
|
|
2021
Q2 | $5.56M | Buy |
213,825
+48,618
| +29% | +$1.26M | ﹤0.01% | 1814 |
|
|
2021
Q1 | $5.23M | Buy |
165,207
+116,958
| +242% | +$4.85M | ﹤0.01% | 1755 |
|
|
2020
Q4 | $2.24M | Buy |
48,249
+7,661
| +19% | +$304K | ﹤0.01% | 2745 |
|
|
2020
Q3 | $1.34M | Sell |
40,588
-240,519
| -86% | -$7.37M | ﹤0.01% | 3010 |
|
|
2020
Q2 | $7.72M | Buy |
281,107
+159,671
| +131% | +$5.25M | 0.01% | 1515 |
|
|
2020
Q1 | $3.63M | Buy |
121,436
+52,597
| +76% | +$1.39M | ﹤0.01% | 1936 |
|
|
2019
Q4 | $1.91M | Sell |
68,839
-95,547
| -58% | -$2.17M | ﹤0.01% | 3035 |
|
|
2019
Q3 | $2.99M | Buy |
164,386
+47,778
| +41% | +$1.06M | ﹤0.01% | 2420 |
|
|
2019
Q2 | $2.86M | Buy |
116,608
+76,831
| +193% | +$1.16M | ﹤0.01% | 2455 |
|
|
2019
Q1 | $378K | Sell |
39,777
-204,277
| -84% | -$1.98M | ﹤0.01% | 4484 |
|
|
2018
Q4 | $2.16M | Buy |
244,054
+218,275
| +847% | +$2.11M | ﹤0.01% | 2590 |
|
|
2018
Q3 | $289K | Buy |
25,779
+6,750
| +35% | +$95.8K | ﹤0.01% | 4878 |
|
|
2018
Q2 | $244K | Buy |
19,029
+870
| +5% | +$12.7K | ﹤0.01% | 4861 |
|
|
2018
Q1 | $307K | Sell |
18,159
-40,201
| -69% | -$609K | ﹤0.01% | 4505 |
|
|
2017
Q4 | $467K | Buy |
58,360
+54,095
| +1,268% | +$434K | ﹤0.01% | 4169 |
|
|
2017
Q3 | $33K | Buy |
4,265
+3,320
| +351% | +$21K | ﹤0.01% | 6201 |
|
|
2017
Q2 | $7K | Sell |
945
-4,743
| -83% | -$30.1K | ﹤0.01% | 6639 |
|
|
2017
Q1 | $42K | Sell |
5,688
-36,245
| -86% | -$266K | ﹤0.01% | 5813 |
|
|
2016
Q4 | $291K | Buy |
41,933
+27,242
| +185% | +$187K | ﹤0.01% | 4959 |
|
|
2016
Q3 | $121K | Buy |
14,691
+3,427
| +30% | +$29K | ﹤0.01% | 5069 |
|
|
2016
Q2 | $91K | Sell |
11,264
-32,413
| -74% | -$204K | ﹤0.01% | 5150 |
|
|
2016
Q1 | $221K | Buy |
43,677
+23,557
| +117% | +$129K | ﹤0.01% | 4991 |
|
|
2015
Q4 | $155K | Sell |
20,120
-354,887
| -95% | -$2.46M | ﹤0.01% | 4974 |
|
|
2015
Q3 | $2.16M | Sell |
375,007
-578
| -0.2% | -$4.5K | ﹤0.01% | 2386 |
|
|
2015
Q2 | $3.44M | Buy |
+375,585
| New | +$4.19M | ﹤0.01% | 2077 |
|
Other funds holding IOVA
MFM
VCM
VPM
ICM
Citigroup's IOVA Position: Q1 2026 in Review
Citigroup reduced its Iovance Biotherapeutics (IOVA) stake by 23% in Q1 2026, selling an estimated $76.2K and leaving 81,725 shares worth $287K. The position accounts for ﹤0.01% of the portfolio, ranked #3816.
Citigroup first reported a position in IOVA in Q2 2015 and has held it in 44 quarters since. The position peaked at $8M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.
- Citigroup held 81,725 shares of Iovance Biotherapeutics worth $287K as of Q1 2026.
- Citigroup sold 23,815 Iovance Biotherapeutics shares in Q1 2026, an estimated $76.2K.
- Iovance Biotherapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3816 holding.
- Citigroup first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 44 quarters since.
- Citigroup's Iovance Biotherapeutics position peaked at $8M in Q1 2024.
- 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.